11 terminated, 7 completed, 6 recruiting, 1 active not recruiting. 22 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Terminated 8, Completed 7, Recruiting 5, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 4 | Recruiting 2, Completed 1, Terminated 1 |
Follow Fate Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FT839 in Autoimmune Diseases FT839 - ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | Phase 1 / Phase 2 | Recruiting | Fate Therapeutics | 446 | 2026-10-01 | 2026-09-02 |
| A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis FT819 - Lupus Nephritis, Systemic Lupus Erythematosus | Phase 2 | Recruiting | Fate Therapeutics | 53 | 2026-07-27 | 2026-09-14 |
| First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma FT536, Biopsy/ Intratumoral Injection/ Gross Tumor Resection, Blood/ Cerebrospinal Fluid/ Tumor Pathology - Astrocytoma, Glioblastoma | Phase 1 | Recruiting | Masonic Cancer Center, University of Minnesota | 9 | 2026-04-23 | 2026-05-01 |
| FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors FT836, Cetuximab, Trastuzumab - Non-Small Cell Lung Cancer, Colorectal Cancer | Phase 1 | Recruiting | Fate Therapeutics | 119 | 2025-11-04 | 2026-09-02 |
| A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease FT819, Fludarabine, Cyclophosphamide - Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | Phase 1 | Recruiting | Fate Therapeutics | 244 | 2024-03-28 | 2026-05-22 |
| FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors FT825, Fludarabine, Cyclophosphamide - Advanced Solid Tumor | Phase 1 | Recruiting | Fate Therapeutics | 351 | 2024-01-05 | 2025-12-09 |
| FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) FT522, Rituximab, Cyclophosphamide - Relapsed/Refractory B-Cell Lymphoma | Phase 1 | Completed | Fate Therapeutics | 20 | 2023-11-16 | 2025-08-22 |
| FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma FT596, Cyclophosphamide, Doxorubicin - Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma | Phase 1 | Withdrawn | Fate Therapeutics | 2022-12-01 | 2023-07-06 | |
| FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors FT536, Cyclophosphamide, Fludarabine - Non Small Cell Lung Cancer, Colorectal Cancer | Phase 1 | Terminated | Fate Therapeutics | 5 | 2022-05-31 | 2023-09-21 |
| FT576 in Subjects With Multiple Myeloma FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine - Multiple Myeloma, Myeloma | Phase 1 | Completed | Fate Therapeutics | 31 | 2021-11-10 | 2025-12-12 |
| FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors FT538, Cyclophosphamide, Fludarabine - Solid Tumor, Adult | Phase 1 | Terminated | Fate Therapeutics | 16 | 2021-10-15 | 2023-09-21 |
| FT819 in Subjects With B-cell Malignancies FT819, Cyclophosphamide, Fludarabine - Lymphoma, B-Cell, Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | Fate Therapeutics | 54 | 2021-07-12 | 2026-03-19 |
| FT538 in Subjects With Advanced Hematologic Malignancies FT538, Cyclophosphamide, Fludarabine - Acute Myeloid Leukemia, AML, Adult | Phase 1 | Terminated | Fate Therapeutics | 42 | 2020-10-17 | 2023-09-21 |
| FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors FT516, Avelumab, Cyclophosphamide - Solid Tumor, Adult | Phase 1 | Terminated | Fate Therapeutics | 12 | 2020-09-07 | 2023-09-21 |
| FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies FT596, Cyclophosphamide, Fludarabine - Lymphoma, B-Cell, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Fate Therapeutics | 98 | 2020-03-19 | 2023-10-26 |
| Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy Genetically engineered NK cells - Hematological Malignancy | Terminated | Fate Therapeutics | 2 | 2019-10-04 | 2022-08-29 | |
| FT516 in Subjects With Advanced Hematologic Malignancies FT516, Rituximab, Obinutuzumab - Acute Myelogenous Leukemia, B-cell Lymphoma | Phase 1 | Terminated | Fate Therapeutics | 72 | 2019-10-04 | 2023-10-26 |
| Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy Allogeneic natural killer (NK) cell - Advanced Solid Tumor, Lymphoma | Terminated | Fate Therapeutics | 20 | 2019-06-11 | 2023-09-21 | |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors FT500, Nivolumab, Pembrolizumab - Advanced Solid Tumors, Lymphoma | Phase 1 | Completed | Fate Therapeutics | 37 | 2019-02-15 | 2023-05-01 |
| FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors FATE-NK100, Cetuximab, Trastuzumab - HER2 Positive Gastric Cancer, Colorectal Cancer | Phase 1 | Completed | Fate Therapeutics | 44 | 2018-01-18 | 2021-11-22 |
Showing 20 of 26. Sign in to see all of them.
Hematologic Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Carcinoma, Renal Cell (5) · Colorectal Neoplasms (5) · Lymphoma (5) · Breast Neoplasms (4) · Carcinoma, Hepatocellular (4) · Carcinoma, Merkel Cell (4) · Head and Neck Neoplasms (4) · Leukemia, Myeloid, Acute (4) · Lymphoma, B-Cell (4) · Melanoma (4) · Pancreatic Neoplasms (4) · Stomach Neoplasms (4) · Carcinoma, Transitional Cell (3)
Cyclophosphamide (13) · fludarabine (13) · Bendamustine Hydrochloride (8) · Interleukin-2 (5) · Cetuximab (4) · Rituximab (4) · Trastuzumab (3) · fludarabine phosphate (3) · Influenza Vaccines (2) · Nivolumab (2) · aldesleukin (2) · atezolizumab (2) · avelumab (2) · daratumumab (2) · obinutuzumab (2)
United States (25) · France (1) · Sweden (1) · United Kingdom (1)
Chris Storgard, MD (2) · Chris Storgard, M.D. (1) · Corey Cutler, MD, MPH, FRCP(C) (1) · Jeff Chou, MD (1) · Rebecca Elstrom, MD (1) · Samuel Dychter, MD (1) · Sarah Cooley, MD (1)